The relationship, structure and profiles of schizophrenia measurements: A post-hoc analysis of the baseline measures from a randomized clinical trial

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Chen, Lei ^a   Phillips, Glenn ^b   Johnston, Joseph ^a   Kinon, Bruce J ^a   Ascher Svanum, Haya ^a   Kollack Walker, Sara ^c   Succop, Paul ^d   Naber, Dieter ^e  

^a ELI LILLY AND COMPANY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c Lilly USA   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA SYMBOL CODING TEST, SUBJECTIVE WELL-BEING UNDER NEUROLEPTICS SCALE SHORT FORM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE EXACERBATION; DRUG EFFICACY; FACTORIAL ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONSET AGE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGIC TEST; QUALITY OF LIFE SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIA OBJECTIVE FUNCTIONING INSTRUMENT; SCHIZOPHRENIFORM DISORDER; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOSIS; QUALITY OF LIFE; STATISTICS; TREATMENT OUTCOME;

ADULT; AGED; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 84455170735     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-203     Document Type: Article

References (20)

1. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35(2):581-190. 10.1038/npp.2009.164, 3055392, 19890258.
2. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM, Naber D. Challenging the assumption that improvement in functional outcomes is delayed relative to improvement in symptoms in the treatment of schizophrenia. Schizophr Res 2010, 118(1-3):176-182. 10.1016/j.schres.2009.12.013, 20080036.
3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13(2):261-276.
4. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389. 10.1192/bjp.134.4.382, 444788.
5. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004, 68(2-3):283-297. 10.1016/j.schres.2003.09.011, 15099610.
6. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001, 50(1-2):79-88. 10.1016/S0920-9964(00)00166-3, 11378316.
7. Phillips G, Chen L, Johnston J, Stauffer V, Kinon BJ, Ascher-Svanum H, Kollack-Walker S, Naber D. Factor analysis and item response theory analysis of the Subjective Wellbeing Under Neuroleptic Treatment scale: Suggestion for item reduction. Int J Neuropsychopharmacol 2010, 13(S1):234.
8. Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA. Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. Schizophr Res 2009, 107(2-3):275-285. 10.1016/j.schres.2008.10.002, 19013769.
9. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit-syndrome. Schizophr Bull 1984, 10(3):388-398.
10. Muthén LK, Muthén BO. Mplus User's Guide 2007, Los Angeles, CA: Muthén & Muthén, 5.
11. Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol 2009, 12(5):715-721. 10.1017/S1461145709000327, 19366489.
12. Karow A, Czekalla J, Dittmann RW, Schacht A, Wagner T, Lambert M, Schimmelmann BG, Naber D. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007, 68(1):75-80. 10.4088/JCP.v68n0110, 17284133.
13. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008, 41(4):125-128. 10.1055/s-2008-1076729, 18651339.
14. Kim JH, Ann JH, Kim MJ. The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia. Compr Psychiatry 2010, 51(2):165-170. 10.1016/j.comppsych.2009.05.004, 20152297.
15. Kim JH, Ann JH, Kim MJ. Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics. J Clin Pharm Ther 2011, 36(2):172-178. 10.1111/j.1365-2710.2010.01175.x, 21366646.
16. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007, 64(5):532-542. 10.1001/archpsyc.64.5.532, 17485605.
17. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, Harvey PD. Predicing schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol Psychiatry 2008, 63(5):505-511. 10.1016/j.biopsych.2007.05.022, 2335305, 17662256.
18. Brekke JS, Raise A, Ansel M, Lencz T, Bird L. Neuropsychological and psychophysiological correlates of psychosocial function in schizophrenia. Schizophr Bull 1997, 23(1):19-28.
19. Gold JM, Goldberg RW, McNary SW, Dixon LB, Lehman AF. Cognitive correlates of job tenure among patients with severe mental illness. Am J Psychiatry 2002, 159(8):1395-1402. 10.1176/appi.ajp.159.8.1395, 12153834.
20. Lipkovich IA, Deberdt W, Csernansky JG, Sabbe B, Keefe RS, Kollack-Walker S. Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. BMC Psychiatry 2009, 9:44. 10.1186/1471-244X-9-44, 2717959, 19602273.